SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Phaarmasia - Quaterly Results

28 May 2025 Evaluate
The sales for the March 2025 quarter moved down -45.64% to Rs. 54.30 millions as compared to Rs. 99.89 millions during the year ago period.The Net Loss for the quarter ended March 2025 is Rs. -5.26 millions as compared to Net Profit of Rs. 4.73 millions of corresponding quarter ended March 2024Operating profit Margin for the quarter ended March 2025 slipped to -4.33% as compared to 5.26% of corresponding quarter ended March 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 54.30 99.89 -45.64 243.69 305.93 -20.34 243.69 305.93 -20.34
Other Income 1.84 1.95 -5.64 7.46 6.62 12.69 7.46 6.62 12.69
PBIDT -4.33 5.26 -182.32 -12.67 -1.58 701.90 -12.67 -1.58 701.90
Interest 0.02 0.05 -60.00 0.16 0.44 -63.64 0.16 0.44 -63.64
PBDT -4.35 5.21 -183.49 -12.83 -2.02 535.15 -12.83 -2.02 535.15
Depreciation 0.79 0.86 -8.14 3.20 3.44 -6.98 3.20 3.44 -6.98
PBT -5.14 4.35 -218.16 -16.03 -5.46 193.59 -16.03 -5.46 193.59
TAX 0.12 -0.38 -131.58 -0.13 -0.28 -53.57 -0.13 -0.28 -53.57
Deferred Tax 0.12 -0.38 -131.58 -0.13 -0.28 -53.57 -0.13 -0.28 -53.57
PAT -5.26 4.73 -211.21 -15.90 -5.18 206.95 -15.90 -5.18 206.95
Equity 68.27 68.27 0.00 68.27 68.27 0.00 68.27 68.27 0.00
PBIDTM(%) -7.97 5.27 -251.43 -5.20 -0.52 906.62 -5.20 -0.52 906.62

Phaarmasia Share Price

102.14 4.31 (4.41%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×